EGFR and cancer: A second classification system is the MESTT (Multinational Association of Supportive Care in Cancer - MASCC; EGFR Inhibitor Skin Toxicity Tool), a complex system that takes into account data reported by the patient, such as changes in quality of life, changes in the time and dose of treatment as related to the adverse effect.16